10 results match your criteria: "Laboratoire TIMC-TheREx UMR 5525 CNRS-Université Grenoble Alpes[Affiliation]"
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third coronavirus leading to a global health outbreak. Despite the high mortality rates from SARS-CoV-1 and Middle-East respiratory syndrome (MERS)-CoV infections, which both sparked the interest of the scientific community, the underlying physiopathology of the SARS-CoV-2 infection, remains partially unclear. SARS-CoV-2 shares similar features with SARS-CoV-1, notably the use of the angiotensin conversion enzyme 2 (ACE2) as a receptor to enter the host cells.
View Article and Find Full Text PDFBiophys J
January 2020
Université Grenoble Alpes, Laboratoire Rhéologie et Procédés, UMR CNRS 5520, Grenoble, France. Electronic address:
Among the many factors influencing fibrin formation and structure (concentration, temperature, composition, pH, etc.), it has been suggested that the polydispersity of fibrinogen may play an important role. We propose here a detailed investigation of the influence of this parameter on fibrin multiscale structure.
View Article and Find Full Text PDFFundam Clin Pharmacol
April 2019
Univ. Grenoble Alpes, HP2, Grenoble, F-38041, France.
Voriconazole (VRC) overdoses are frequent and expose patients at high risk of adverse effects. This case-control study performed in hematological patients who benefited from VRC therapeutic drug monitoring from January 2012 to December 2015 aimed to identify risk factors of VRC overdose. Pharmacogenetic, biological, and demographic parameters at the time of VRC trough concentration (C ) were retrospectively collected from medical records.
View Article and Find Full Text PDFPLoS One
March 2019
Laboratoire de Bactériologie, Grenoble-Alpes University Hospital, Grenoble, France.
Staphylococcus aureus bacteremia is one of the most frequent severe bacterial infections worldwide, with an associated mortality of about 20-40% in developed countries. In 2013, we noted an increase in this infection in the teaching hospital in Grenoble, France, compared to 2012. The mean incidence of S.
View Article and Find Full Text PDFPharmacogenomics
August 2017
Laboratoire de Pharmacologie - Toxicologie, Centre Hospitalier Universitaire Grenoble Alpes, CS 10217, F-38043 Grenoble CEDEX 9, France.
How pharmacogenetics modulates the inhibitory effects of inflammation on voriconazole trough concentration (Cmin) remains unknown. In 29 recipients of allogeneic hematopoietic stem cell transplantation retrospectively studied, both a genetic score (which aggregated CYP2C19 and CYP3A genotypes) and inflammation significantly influenced voriconazole Cmin (n = 260). A trend toward (p = 0.
View Article and Find Full Text PDFMol Ther Oncolytics
December 2016
Laboratoire TIMC-TheREx UMR 5525 CNRS-Université Grenoble Alpes, La Tronche, France; Département de Biochimie Toxicologie Pharmacologie, UM Biochimie des Enzymes et des Protéines, Institut de Biologie et Pathologie, C.H.U. de Grenoble, Grenoble, France.
Live-attenuated bacterial vectors for antigens delivery have aroused growing interest in the field of cancer immunotherapy. Their potency to stimulate innate immunity and to promote intracellular antigen delivery into antigen-presenting cells could be exploited to elicit a strong and specific cellular immune response against tumor cells. We previously described genetically-modified and attenuated vectors able to deliver protein antigens into antigen-presenting cells, through Type 3 secretion system of the bacteria.
View Article and Find Full Text PDFEur J Clin Microbiol Infect Dis
June 2016
Laboratoire de Parasitologie-Mycologie, Institut de Biologie et de Pathologie, CHU de Grenoble, Grenoble, France.
The diagnosis and follow-up of candidemia still rely on blood cultures (BCs). In vitro studies show that antifungals can significantly modify the result of blood culture not containing adsorbing agents. We aimed to evaluate, under clinical conditions, the impact on BC yeast detection of systemic antifungal therapy (SAT).
View Article and Find Full Text PDFTher Drug Monit
October 2015
*Laboratoire de Pharmacologie Toxicologie; †Laboratoire de Parasitologie-Mycologie, Institut de Biologie et Pathologie, Grenoble University Hospital; ‡Université Grenoble Alpes; §INSERM U1042, HP2; ¶Medical Oncology-Hematology Unit, Grenoble University Hospital; and ‖Laboratoire TIMC-TheREx, UMR 5525 CNRS-UJF, Université Joseph Fourier, Grenoble, France.
Background: With the constantly growing incidence of invasive fungal infections, any failure of antifungal treatment is worrying. Azole antifungals present high variability of their plasma trough concentrations (Cmin), justifying their therapeutic drug monitoring (TDM). The authors aimed to develop a simple bioassay to determine the in vitro growth inhibition diameter (ID) and to correlate this ID with Cmin in patients treated with voriconazole or posaconazole.
View Article and Find Full Text PDFJ Antimicrob Chemother
September 2015
Laboratoire de Parasitologie-Mycologie, Institut de Biologie et de Pathologie, CHU de Grenoble, Grenoble, France Laboratoire TIMC-TheREx, UMR 5525 CNRS-UJF, Université Grenoble Alpes, Grenoble, France.
Objectives: MDR Candida strains are emerging. Next-generation sequencing (NGS), which enables extensive and deep genome analysis, was used to investigate echinocandin and azole resistance in clinical Candida isolates.
Methods: Six genes commonly involved in antifungal resistance (ERG11, ERG3, TAC1, CgPDR1, FKS1 and FKS2) were analysed using NGS in 40 Candida isolates (18 Candida albicans, 15 Candida glabrata and 7 Candida parapsilosis).
Antimicrob Agents Chemother
April 2015
Université Grenoble Alpes, Grenoble, France INSERM U1042, HP2, Grenoble, France Laboratoire de Pharmacologie-Toxicologie, Grenoble University Hospital, Grenoble, France.
Voriconazole (VRC) plasma trough concentrations (Cmin) are highly variable, and this could affect treatment efficacy and safety in patients undergoing allogeneic hematopoietic stem cell transplantation (AHSCT). We aimed to describe the intra- and interindividual variation of VRC Cmin throughout the course of VRC therapy and to identify the determinants of this variation. Clinical data, medications, and VRC Cmin (n = 308) of 33 AHSCT patients were retrospectively collected.
View Article and Find Full Text PDF